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Abstract Postoperative adhesions are the most frequent
complication of peritoneal surgery, causing small bowel
obstruction, female infertility and chronic pain. This pilot
study assessed the efficacy of a sprayable polyethylene
glycol (PEG) barrier in the prevention of de novo
adhesions. 16 patients undergoing laparoscopic gyneco-
logical surgery were randomly assigned by shuffled
sealed envelopes to receive either the adhesion barrier
or no adhesion prevention. Incidence and severity of
adhesions were scored at eight sites in the pelvis and
reassessed by second look laparoscopy. Adhesion preven-
tion was considered successful if no de novo adhesion
were found at second look laparoscopy. One patient was
excluded before randomization. Nine patients were
randomized to treatment and six patients to control
group. De novo adhesions were found in 0/9 patients
who received the PEG barrier compared to 4/6 without
adhesion prevention (0% vs. 67%, P=0.01). Reduction in
adhesion score was significantly greater in patients receiv-
ing PEG barrier (−2.6 vs. −0.06, P=0.03). Meta-analysis of
three randomized trials demonstrated that PEG barrier
reduces the incidence of adhesions (odds ratio [OR]=
0.27; 95% CI 0.11–0.67). From this study, PEG barrier
seems effective in reducing postoperative formation of de
novo adhesions.
Keywords Tissue adhesions . Laparoscopy . Polyethylene
glycol . Hydrogels . Randomized controlled trial
Background
Adhesions develop after gynecological surgery in the pelvic
cavity in almost all cases and cause significant morbidity
[1]. In a large population-based study of gynecological
pelvic surgery, the readmission rate directly or probably
related to adhesions was 13.9%, and the introduction of less
invasive techniques, such as laparoscopy, did not seem to
reduce this adhesion related morbidity [2]. The incidence of
adhesive small bowel obstruction (ASBO) after oncologic
gynecological surgery is about 11% [3]. Adhesions are the
leading cause of secondary female infertility worldwide [4,
5], and an important cause of chronic pelvic pain [6, 7]. In
addition, adhesiolysis during reoperation is time-consuming
and exposes the patient to the risk of unintended injury
such as enterotomy [1, 8].
Adhesion barriers or anti-adhesive agents are needed
because refinements in surgical techniques do not seem to
be sufficient in reducing adhesion-related morbidity. Several
products have come to the market ranging from membranes
for selective coverage of injured peritoneal areas to liquids for
broad nonspecific coverage. An important drawback of the
available membranous adhesions barriers is the difficulty of
handling them during laparoscopic procedures. Alternatives to
membranes for laparoscopic use are sprays that are easily
applied intraperitoneally through trocars at sites that need to
be covered. Recently, a sprayable polyethylene glycol (PEG)
anti-adhesion barrier was developed for anti-adhesive pur-
poses (SprayGel; Confluent Surgical Inc., Waltham, MA). The
PEG adhesion barrier consists of two liquid precursor
solutions that quickly react to form a hydrogel after being
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sprayed and mixed in the abdomen. One of the precursors
contains a small concentration of methylene blue allowing
visualization of the area covered and the thickness of the
hydrogel layer during laparoscopy. The hydrogel is biode-
gradable and physically separates the injured peritoneal sites
in order to promote adhesion free peritoneal regeneration.
The PEG anti-adhesion spray proved to be effective in
rodent and porcine models with 75% reduction of the
incidence of adhesions in a rat cecal abrasion model and
60% reduction in a porcine uterine horn model [9, 10]. Four
human randomized controlled trials (RCTs) have been
performed: two in patients undergoing laparoscopic or open
myomectomy and two in patients undergoing loop ileostomy
closure [11–14]. No RCT has included patients undergoing
laparoscopic surgery alone, and all RCTs included a specific
group of patients rather than investigating the various
common types of laparoscopic benign gynecological
surgery. The use of PEG spray was correlated with a
reduction in extend and tenacity of adhesions in these
RCTs. However, reductions in adhesion incidence — in
contrast to reduction in adhesion extend or tenacity — is
particularly important for predicting the value of an anti-
adhesive product reducing ASBO and unintended organ
injury during adhesiolysis. We undertook a small prospec-
tive randomized controlled study to evaluate the PEG spray
on adhesion formation in women undergoing common
laparoscopic gynecological procedures. In addition, we
performed a meta-analysis of reported studies, including
the present one, focusing on the efficacy of PEG spray in
reducing the incidence of adhesions.
Materials and methods
The study was a randomized single-blinded (patient) study.
Patients who were scheduled for laparoscopic treatment of
benign gynecologic disease involving ovaries, pelvic side-
walls, fallopian tubes or uterus were assessed for eligibility
between September 2002 and March 2004. Inclusion
criteria were as follows: age ≥18 years; the patient might
benefit from and agrees to return for second look
laparoscopy (SLL); and the patient agrees to use contra-
ception until SLL was conducted.
Pregnant and lactating patients were excluded, as well as
patients with known or suspected malignancy. Peroperative
exclusion criteria were endometriosis classified as stage IV,
using the Revised American Society for Reproductive
Medicine Classification of Endometriosis scoring system
and if complete adhesiolysis was not possible [15].
At the end of index laparoscopic surgery and before
removal of all instruments, patients were randomly
assigned — via shuffled sealed envelopes — to treatment
with PEG or no treatment groups. The PEG barrier was
sprayed at all sites of surgical injury with the potential for
adhesion formation. SLL was planned to evaluate adhesion
formation. The surgeon performing SLL was blinded for
the treatment group.
The study protocol was approved by the local Medical
Ethical Committee and designed according to the ethical
considerations described in the revised version of the
Declaration of Helsinki (October 2008, Seoul). All patients
gave written informed consent. The study was investigator-
driven. PEG was kindly donated by Confluent, Surgical Inc
(Waltham, MA, USA). The trial was registered at clinical
trials.gov with identifier: NCT01187680.
Adhesion scoring
The incidence of patients with and without any adhesion
was assessed in both initial and second look laparoscopies.
All surgical procedures were performed by the same
surgeons (EB and HV). Adhesions at SLL were classified
as de novo adhesions or reformed adhesions. De novo
adhesions are adhesions that are newly formed following
the first laparoscopy at sites without any former adhesions.
Reformed adhesions are adhesions that formed at the sites
of adhesiolysis during the first laparoscopy [16].
Adhesions were graded using the Local Adhesion
Barrier Scoring System (LABS) score, based on the
modified version of the American Fertility Society score
system [17]. The LABS is an integrated score system
comprising the adhesion’s morphology and extend of the
site covered with adhesions (Table 1). The LABS score
differs from the modified version of the American Fertility
Society score system; adhesions are scored at a lower
number of sites that are more specific to gynecologic
surgery. Adhesions were systematically evaluated for
incidence and LABS score at eight sites: both left and right
tubes, ovaries and pelvic sidewall and the anterior and
posterior uterus. For each patient, the total LABS score was
calculated as the mean of LABS scores at these eight
separate locations.
Table 1 Local Adhesion Barrier Scoring (LABS) system
LABS adhesion score
Tenacity Extend Score
None None (0% covered) 0
Mild Localized (<33% covered)) 1
Mild Moderate (33–67% covered) 2
Mild Extensive (>67% covered) 4
Severe Localized (<33% covered)) 4
Severe Moderate (33–67% covered) 8
Severe Extensive (>67% covered) 16
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Safety aspects
All patients were treated in day care. Postoperatively,
patients were controlled for temperature, pain, hemody-
namic changes and signs of bleeding in the recovery area.
Outcomes
The primary outcome for this pilot study was the number of
patients with de novo adhesions. Secondary outcomes were
change in the number of sites covered with adhesions and
change in LABS adhesion score.
The number of patients with any adhesions is the most
preferable outcome of adhesion prevention studies. However,
as the sample size of this pilot study would be inadequate to
provide in sufficient power on this outcome, we addressed
this outcome in meta-analysis of systematically searched
studies on PEG adhesion barrier.
Power analysis
Based on animal studies, the incidence of de novo
adhesions was estimated at 30% in the PEG group and
90% in the control group [10]. Fourteen patients in each
arm of the study were needed to detect such difference with
80% power and 5% two-tailed significance threshold at 1:1
randomization. Accounting for loss to follow-up, a mini-
mum of 30 patients were to be randomized.
Statistical analysis
All statistical tests performed were two-tailed with signif-
icance was determined at the 5% level. Unpaired t-test was
used for the testing of continuous data and Fisher’s exact
test for dichotomous data. All statistical analyses were
performed using SPSS 16.0.2 (SPSS inc., Chicago, ILL).
Meta-analysis
A comprehensive search of Pubmed and Embase search
was performed on July 1, 2011 to identify papers published
in peer-reviewed journals from RCTs in surgical or
gynaecological patients for the intervention with PEG and
outcome adhesions. In Pubmed, randomized trials were
identified via the Cochrane Highly Sensitive Search
Strategy for identifying randomized trials (sensitivity- and
precision-maximizing version) [18]. We selected random-
ized trials in Embase using the top performing search
strategy (minimizing difference between sensitivity and
specificity version) described by Wong et al. [19]. Relevant
RCTs were searched for data on the number of patients with
any adhesions. The incidence of adhesions was expressed
in odds ratio (OR) for meta-analysis. A fixed-effects model
was applied for meta-analysis. In the presence of significant
heterogeneity, the random-effects model was applied.
Heterogeneity was tested with Cochrane Q-test and I2 test.
An I2 value ≥50% or P value <0.05 was considered
significant. Meta- analysis was carried out using Review
Manager 5.0 (The Cochrane Collaboration, Copenhagen,
Denmark).
End of study
The study was prematurely ended due to financial and
organizational reasons. During the conduct of the study, the
clinical trial insurance unexpectedly required a separate fee
for both laparoscopic procedures in each patient.
Results
A total of 16 eligible patients gave informed consent.
Fifteen underwent successful laparoscopic gynecological or
fertility surgery and were randomized. One patient had
severe pelvic adhesions that could not be lysed completely
and was excluded before randomization. There were no
significant differences between the PEG and control group
at index laparoscopy in age, type of surgical procedure,
history of prior surgery, Chlamydia serology and smoking
status at baseline (Table 2). Adhesiolysis was performed in
14 patients.
At index laparoscopy, there was a non-significant trend
towards more sites covered with adhesions (5.1±2.3 vs. 3±
2.2; P=0.10) and higher LABS score (3.7±2.8 vs. 2.4±3.0;
P=0.40) in the PEG group (Table 3). Time of surgery was
comparable between the PEG and control group at index
laparoscopy. Time period between initial and second look
laparoscopies was similar for both groups: 27.9±11.5 days
in the PEG group and 28.0±17.6 in the control group
(P>0.99).
All 15 randomized patients underwent SLL. De novo
adhesions were found in 0/9 patients in the PEG group
(0%) compared to 4/6 (67%) of patients in the control
group (P=0.01). Patients in the PEG group had a decrease
in LABS score compared to an increase in the control group
(−2.6±2.1 vs. 0.1±1.7; P=0.03). This decrease was most
prominent at the ovaries and fallopian tubes sites. The
change in the number of sites covered with adhesions
was −2.4±2.0 for patients treated with PEG spray
compared to 0.8±2.3 for control patients (P=0.01). There
were no significant differences in the absolute incidence,
sites covered with adhesions and LABS scores between the
PEG group and controls at SLL (Table 4). There were no
post- operative complications in both groups.
Although no significant differences were found in the
incidence of adhesions at any of the specific sites at SLL,
Gynecol Surg (2012) 9:29–35 31
the effect of PEG appeared maximal at the ovaries. The
incidence of adhesions around the ovaries was reduced
between index laparoscopy and SLL in the PEG treated
group by 33% and 44% for the right and left ovaries,
respectively. On the contrary, a 17% and 33% increase in
incidence of adhesions around the right and left ovaries,
respectively, was seen in control patients.
Meta-analysis of adhesion incidence
A total of 85 papers from peer-reviewed journals were
identified using the search strategy. Five papers were
identified studying the efficacy of PEG on adhesion
formation after peritoneal surgery in an RCT [11–14, 20].
The number of patients with any adhesions could be
assessed from three papers investigating patients undergo-
ing myomectomy [11, 13, 20]. One paper was excluded
because it described an interim analysis and results from
the completed study were described in another paper [11,
20]. Thus, two RCTs and the present study remained for
meta-analysis. In all here studies a trend towards a lower
overall incidence of adhesions was demonstrated in PEG
treated patients. Pooled data, using a fixed effects model,
showed a significant reduction of the incidence of adhe-
sions with an OR of 0.27 (95% CI 0.11–0.67; P=0.005,
Fig. 1).
Discussion and conclusion
From this study, PEG anti-adhesion barrier seems effective
in the prevention of de novo adhesions in common
gynecological laparoscopic procedures, but especially in
fertility enhancing procedures. Furthermore, there was a
significant difference in change of LABS score favoring
patients treated with PEG adhesion barrier. Meta-analysis
also showed a significant reduction in the total incidence
of adhesions.
The PEG anti-adhesion barrier has a set of unique
characteristics compared to other existing barriers. The
Table 3 Adhesions at initial
laparoscopy
SLL second look laparscopy
aMean±SD
PEG Control P value
Patients with any adhesion 8/9 (89%) 5/6 (83%) >0.99
Adhesion sites 5.1±2.3a 3±2.2a 0.10
LABS score (mean) 3.7±2.8a 2.4±3.0a 0.44
• Left ovary 5.1±4.9 2.0±3.3 0.17
• Right ovary 5.8±6.0 4.0±6.2 0.59
• Left fallopian tube 6.4±5.8 2.0±3.3 0.08
• Right fallopian tube 6.2±5.7 3.5+6.3 0.42
• Left pelvic side wall 3.3±3.2 1.3±3.3 0.27
• Right pelvic side wall 1.6±2.8 4.3±6.5 0.36
• Anterior uterus 0.2±0.7 0.0±0.0 0.35
• Posterior uterus 1.2±1.7 2.7±2.1 0.19
Time of surgery (min) 151.9±29.5a 146.7±47.8a 0.82
Time to SLL (days) 27.9±11.5a 28.0±17.6a >0.99
Table 2 Baseline characteristics
aMean±SD
PEG Control P value
Number of randomized patients 9 6
Age 30.1±5.7a 34.5±4.3a 0.12
Type of surgical procedures performed
Adhesiolysis 8 (89%) 5 (83%) >0.99
Salpingotomy/salpingectomy 4 (44%) 2 (33%) >0.99
Cystectomy 2 (22%) 3 (50%) 0.33
Laparotomy 0/9 (0%) 0/6 (0%) >0.99
Laparoscopy 5/9 (56%) 5/6 (83%) 0.58
Positive Chlamydia serology 4/9 (44%) 1/6(17%) 0.58
Smoker 1/9 (11%) 0/6 (0%) >0.99
Completed SLL 9 (100%) 6 (100%) >0.99
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formula of two liquid PEG precursors that rapidly polymerize
into a solid hydrogel, allows the surgeon to laparoscopically
apply a barrier with the characteristics of a site specific barrier
and the ease of application of a liquid [12]. Most site specific
barriers are solid membranes that are difficult to apply
laparoscopically. Site specific adhesion barriers seem most
efficacious against adhesion (re)formation as they remain on
the exact place of application during mesothelial healing. In
the study of Ferland et al. both uterine horns and opposing
peritoneum in a porcine model were abraded. One side was
randomly assigned to coverage with a 1- to 2-mm-thick layer
of PEG adhesion barrier. The barrier remained in place, and
at SLL a significantly lower incidence of adhesion was found
at the treated sides, demonstrating that the PEG adhesion
barrier acts as a site-specific adhesion barrier [10]. The
methylene blue dye makes it easy to assess if an area is
sufficiently covered with the PEG anti-adhesion barrier. PEG
molecules polymerize without the need of an external energy
source or excess heat production and the hydrogel remains
intact for 5–6 days, which is long enough for peritoneal
layers to heal [21]. When degrading, the hydrogel falls apart
in water-soluble PEG molecules that are easily resorbed and
cleared in the urine [22].
Although a small number of patients could be included
in this trial, our findings support those of earlier studies
demonstrating that PEG spray is a highly efficacious site
specific barrier for laparoscopic use. The incidence of
adhesions could be assessed from two previous RCTs in
patients undergoing myomectomy [11, 13]. In the present
study and the two RCTs, a trend towards a lower overall
Fig. 1 Results from meta-analysis on the efficacy of PEG adhesion barrier reducing the total incidence of adhesions
Table 4 Adhesions at second
look laparoscopy
aMean±SD
bΔ = difference between index
laparoscopy and second look
laparoscopy
Outcome PEG Control P value
Patients with any adhesion 7/9 (78%) 6/6 (100%) 0.49
Patients with de novo adhesions 0/9 (0%) 4/6 (67%) 0.01
Adhesions (number of sites) 2.7±2.4a 3.8±1.7a 0.29
Δ Adhesions (number of sites)a −2.4±2.0a 0.8±2.3a 0.01
LABS score (Mean) 1.2±1.3a 2.4±2.4a 0.29
• Left ovary 0.7±0.9 2.2±3.0 0.28
• Right ovary 2.9±5.2 5.5±6.4 0.43
• Left fallopian tube 2.2±3.3 1.7±1.4 0.66
• Right fallopian tube 2.3±2.8 2.8±6.5 0.86
• Left pelvic side wall 1.0±2.6 0.7±1.0 0.74
• Right pelvic side wall 0.0±0.0 4.0±6.7 0.20
• Anterior uterus 0.0±0.0 0.0±0.0 1.00
• Posterior uterus 0.3±0.5 2.5±3.1 0.15
Δ LABS scoreb (mean) −2.6±2.1a 0.1±1.7a 0.03
• Left ovary −4.4±5.1 0.2±2.2 0.03
• Right ovary −2.9±4.8 1.5±5.3 0.13
• Left fallopian tube −4.2±5.0 −0.3±4.0 0.12
• Right fallopian tube −3.9±4.0 −0.7±1.2 0.05
• Left pelvic side wall −2.3±2.8 −0.7±3.7 0.38
• Right pelvic side wall −1.6±2.8 −0.3±0.8 0.24
• Anterior uterus −0.2±0.7 0.0±0.0 0.35
• Posterior uterus −0.9±1.5 −0.2±2.7 0.57
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incidence of adhesions was demonstrated in PEG treated
patients. Pooled data showed a significant reduction of the
incidence of adhesions in our meta-analysis. Complete
adhesion prevention is of particular importance as it is the
only means of providing a definitive protection against all
adhesion related complications, such as infertility, ASBO
and inadvertent enterotomies.
A limitation of this study is the analysis of adhesion
prevention and not the clinical complications of adhesions,
such as infertility or ASBO. Infertility as an endpoint is
difficult to assess because failure to attain pregnancy is a
multi-factorial endpoint. To assess the efficacy of adhesion
barriers on fertility, a randomised trial is required in
subfertile patients due to tubal pathology, which compares
use of a barrier to no treatment after adhesiolysis and
compares time to natural conception. Oxidized regenerating
cellulose (Interceed®, Ethicon, Sommerville, NJ) is the
only adhesion barrier that was proven to increase pregnancy
rate in an RCT [23]. However, oxidized regenerating
cellulose has limitations because it is difficult to handle
laparoscopically and can cause adverse adhesiogenic effects
in the presence of blood [24, 25]. Studies evaluating the
efficacy of adhesion barriers in reducing the number of
ASBO and enterotomies are rare. The incidence of these
complications is relative low, thus a large number of
patients is needed to demonstrate a significant effect.
Modified sodium hyaluronic acid (HA) and carboxymethyl-
cellulose (Seprafilm®; Genzyme Corporation, Cambridge,
MA) reduced the number of ASBO requiring reoperation or
found at autopsy by 45% in a study of 1,701 patients who
underwent benign colorectal surgery [26]. This barrier has
limitations because it cannot easily be applied at laparoscopy.
Change in adhesion score can be difficult to interpret as an
outcomemeasure for adhesion prevention because the adhesion
score at baseline influences themaximal effect. However, in our
study, not only the size but also the direction of the effect
differed between the groups. There was a marked decrease in
LABS adhesion score in PEG treated group, while patients in
the control group had a slight increase in adhesion score.
To study the efficacy of adhesion barriers by means of a
second look procedure is becoming increasingly difficult. First,
it is deemed more and more unethical to perform an invasive
second procedure just for scientific purposes. Second, the
benefit of SLL as part of fertility surgery is questionable. Today,
women have more access to alternative treatment modalities to
become pregnant such as in vitro fertilization [27]. Future
adhesion prevention studies expectedly have to rely on non-
invasive techniques to evaluate adhesion formation. For long,
this has been considered impossible but recent studies
show promising results of cine-MRI as a non-invasive
diagnostic tool for the detection of adhesions [28]. More
experience is needed to delineate the value of cine-MRI as
an alternative to SLL in adhesion prevention studies.
Sprayable barriers that can be introduced via a laparoscopic
trocar and handled with ease in the abdominal-pelvic cavity are
of surplus value in the therapeutic arsenal of adhesion
preventive agents. Clinical trials have demonstrated that
laparoscopy only reduces the extend of adhesions but does
not decrease the incidence of adhesions [29, 30]. Maximal
efforts to prevent adhesion formation in fertility surgery
should therefore comprise laparoscopy as well as an adhesion
barrier. Although a large number of agents show adhesion
reduction in animal models, only a few demonstrated such
effects in RCT in humans [31–33]. PEG is one of a few
barriers that has been evaluated in both gynecological and
gastrointestinal patients and was found to be effective in both
our study and previous RCTs [11, 13, 14, 20]. However, more
research is needed to investigate the effect on adhesion related
complications, such as ASBO and infertility.
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